Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Very low nicotine tobacco refers to tobacco products, primarily combustible types such as cigarettes, that have been engineered to contain nicotine at levels so low (typically ≤0.4 mg/g tobacco, or ~95% less than conventional cigarettes) that they are minimally addictive or nonaddictive. These products deliver less nicotine, thereby reducing or eliminating the addictive properties of tobacco while maintaining the toxicant exposure associated with tobacco combustion. The mechanism of action is a reduction of nicotine delivery to the central nervous system, lowering reinforcement and dependence. Clinical evidence suggests switching to very low nicotine tobacco reduces cigarette consumption, dependence, and may increase quit attempts, but these products are not safer than conventional tobacco with regard to carcinogen/toxin exposure, as the risks primarily result from combustion products rather than nicotine itself[1][2][5]. No medicinal or approved cessation claims exist; rather, these are under consideration as population-level harm reduction tools or regulatory public health interventions, such as a possible FDA-mandated nicotine cap[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on very low nicotine tobacco.